Vertex Pharmaceuticals Inc (VRTX)
Interest coverage
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | 3,832,000 | 3,877,000 | 3,965,600 | 4,045,500 | 4,307,400 | 4,151,600 | 4,079,400 | 2,935,200 | 2,782,100 | 2,809,311 | 2,514,538 | 3,391,079 | 3,174,949 | 2,961,237 | 2,286,724 | 1,790,058 | 1,453,421 | 838,894 | 909,167 | 803,048 |
Interest expense (ttm) | US$ in thousands | 44,100 | 45,100 | 47,900 | 51,300 | 54,800 | 58,300 | 59,855 | 60,733 | 61,511 | 62,699 | 61,300 | 59,693 | 58,151 | 56,112 | 56,804 | 57,770 | 58,502 | 62,997 | 67,135 | 70,453 |
Interest coverage | 86.89 | 85.96 | 82.79 | 78.86 | 78.60 | 71.21 | 68.15 | 48.33 | 45.23 | 44.81 | 41.02 | 56.81 | 54.60 | 52.77 | 40.26 | 30.99 | 24.84 | 13.32 | 13.54 | 11.40 |
December 31, 2023 calculation
Interest coverage = EBIT (ttm) ÷ Interest expense (ttm)
= $3,832,000K ÷ $44,100K
= 86.89
Interest coverage ratio is a financial metric used to evaluate a company's ability to meet its interest obligations on debt. It is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expenses. A higher interest coverage ratio indicates that the company is more capable of servicing its debt.
In the case of Vertex Pharmaceuticals, Inc., the interest coverage ratio was not available for Q4 2023, Q3 2023, Q2 2023, and Q1 2023. However, in Q2 2022 and Q1 2022, the interest coverage ratios were 90.47 and 52.59, respectively. This indicates that Vertex Pharmaceuticals, Inc. had a strong ability to cover its interest expenses during those periods.
It is important to note that the absence of data for the most recent quarters makes it challenging to assess the current financial health of the company in terms of its ability to cover its interest expenses. Further analysis and monitoring of Vertex Pharmaceuticals, Inc.'s financial performance will be required to gain a more comprehensive understanding of its interest coverage ratio and overall financial stability.
Peer comparison
Dec 31, 2023
See also:
Vertex Pharmaceuticals Inc Interest Coverage (Quarterly Data)